FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and pharmacology and can be used for prevention and correction of neurodegenerative diseases caused by oxidative brain injury and accompanied by functional disorders of central nervous system (CNS).
EFFECT: method for preventing and correcting metabolic and functional CNS disorders under stress conditions involves administration of a protective agent possessing antioxidant properties, such as deuterium depleted water for not less than 42 days.
1 cl, 6 dwg, 3 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF THE TREATMENT OF THE BRAIN IN ACUTE HYPOXIA WITH HYPERCAPNIA | 2022 |
|
RU2803387C1 |
NEUROPROTECTIVE PHARMACEUTICAL AGENT | 2013 |
|
RU2528914C1 |
ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT POTASSIUM COMENATE | 2012 |
|
RU2514632C1 |
PHARMACOLOGICAL NEUROPROTECTIVE DRUG | 2014 |
|
RU2561045C1 |
USE OF L-CARNOSINE FOR PRODUCING NANOPREPARATION POSSESSING ANTIHYPOXIC AND ANTIOXIDANT ACTIVITY | 2012 |
|
RU2482867C1 |
METHOD FOR PREPARING AGENT HAVING NEUROPROTECTIVE, METABOLIC ACTION | 2023 |
|
RU2826494C1 |
LIPOIC ACID MYCELIAL COMPLEX WITH CARNOSINE FOR MAMMALS PROTECTION AGAINST OXIDATIVE STRESS | 2016 |
|
RU2647435C2 |
AGENT POSSESSING ANTIRADICAL, CEREBROPROTECTIVE AND ANTIISCHEMIC PROPERTIES | 2010 |
|
RU2445090C1 |
CEREBROPROTECTIVE AGENT | 2017 |
|
RU2648451C1 |
METHOD FOR PREPARING LITHIUM SALT OF COMENIC ACID AND USING IT AS ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE AGENT | 2011 |
|
RU2477722C1 |
Authors
Dates
2020-03-18—Published
2019-09-27—Filed